NCT00878800View on ClinicalTrials.gov

A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Dose Escalation: Solid TumorsMTD: Soft Tissue Sarcomas
Interventions
DRUG

PXD101

Administered in combination with doxorubicin (BelDox)

DRUG

Doxorubicin

Administered in combination with PXD101 (BelDox)

Trial Locations (3)

DK-8000 C

Århus Hospital, Department of Oncology, Aarhus

DK-2730

Herlev Hospital, Department of Oncology, Herlev

SM2 5PT Surrey

The Royal Marsden NHS Trust, Cancer Research, Surrey

Sponsors
All Listed Sponsors
collaborator

Spectrum Pharmaceuticals, Inc

INDUSTRY

lead

Valerio Therapeutics

INDUSTRY

NCT00878800 - A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas | Biotech Hunter | Biotech Hunter